French Pharma Stock News

In recent days, the US FDA accepted a priority review of Sanofi’s supplemental application for Tzield, aiming to extend its use to children aged one year and older with stage 2 type 1 diabetes, supported by interim PETITE-T1D Phase 4 data and a target decision date of April 29, 2026. This accelerated review could meaningfully broaden Tzield’s eligible pediatric population, underscoring Sanofi’s efforts to address early-stage autoimmune disease in very young patients. We’ll now examine how...

In recent days, Schneider Electric announced plans to invest over US$700 million in its U.S. operations over the next two years, upgrading, expanding and opening facilities across multiple states and adding more than 1,000 jobs to support energy infrastructure, AI growth and domestic manufacturing. This move signals a deeper commitment to the U.S. market and energy security, potentially reinforcing Schneider Electric’s role in supplying critical infrastructure for AI and electrification...

Verimatrix SA ( EPA:VMX ) shareholders would be excited to see that the share price has had a great month, posting a...

Etablissements Maurel & Prom (ENXTPA:MAU) has cleared a key regulatory hurdle in Colombia, with the National Hydrocarbons Agency approving its acquisition of a 61% working interest and operatorship in the Sinu-9 gas licence. See our latest analysis for Etablissements Maurel & Prom. The Colombian approval comes at a time when momentum in Etablissements Maurel & Prom’s shares has picked up, with a 1-day share price return of 7.22% and a 7-day share price return of 21.22%. The 5-year total...

Alstom (ENXTPA:ALO) has just reported three fresh rolling stock wins worth about €2.5b across the Americas and Europe, adding to a recent €920 million Mexico contract that has put the stock back on investor radar. See our latest analysis for Alstom. The fresh contract wins appear to have fed into stronger momentum, with a 30-day share price return of 16.78% and a 90-day share price return of 19.53%, while the 1-year total shareholder return of 20.55% contrasts with a 5-year total shareholder...

It's not a stretch to say that Gaztransport & Technigaz SA's ( EPA:GTT ) price-to-earnings (or "P/E") ratio of 16.4x...

écomiam SA ( EPA:ALECO ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...

Those holding Biosynex SA ( EPA:ALBIO ) shares would be relieved that the share price has rebounded 25% in the last...

There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...

With a price-to-earnings (or "P/E") ratio of 13.7x Bourse Direct SA ( EPA:BSD ) may be sending bullish signals at the...

Those holding Implanet S.A. ( EPA:ALIMP ) shares would be relieved that the share price has rebounded 34% in the last...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

When close to half the companies in France have price-to-earnings ratios (or "P/E's") above 17x, you may consider...

Key Insights The considerable ownership by private companies in Sodexo indicates that they collectively have a greater...

ERAMET S.A. ( EPA:ERA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Taking...

Nicox S.A. ( EPA:ALCOX ) is possibly approaching a major achievement in its business, so we would like to shine some...

Why L'Oréal is on investors' radar today L'Oréal (ENXTPA:OR) has drawn attention after a period where the share price has slipped over the month and past 3 months, despite a positive 1 year total return and measured multi year gains. See our latest analysis for L'Oréal. The recent 1-month share price decline of 2.54% and 3-month share price decline of 4.21% contrast with a 1-year total shareholder return of 9.43%. This suggests that shorter-term momentum has faded, while longer-term holders...

Airbus (ENXTPA:AIR) has caught investor attention after delivering 793 commercial aircraft in 2025, slightly above its revised target, despite earlier production issues with fuselage panels and its A320 model. See our latest analysis for Airbus. The solid delivery figures sit alongside a 7 day share price return of 6.12% and a 1 month share price return of 5.74%. The 1 year total shareholder return of 33.22% and 5 year total shareholder return of 147.95% point to momentum that has been...

Eurofins Scientific (ENXTPA:ERF) is back in focus after recent share price moves, with investors weighing its €7,144.3m revenue base and €380.9m net income against mixed short term and multi year total returns. See our latest analysis for Eurofins Scientific. Recent trading has been fairly muted, with a 1 month share price return of 5.41% but a 3 year total shareholder return decline of 6.69% and a 5 year total shareholder return decline of 10.72%, suggesting longer term momentum has been...

Voltalia announced that it has begun construction of the Artemisya hybrid cluster in Uzbekistan, combining 100 megawatts / 200 megawatt-hours of storage and 100 megawatts of wind under long-term power purchase agreements signed with the Uzbek government in 2025, with commissioning targeted for 2027. This project, the first hybrid solar, wind and storage cluster in Central Asia, aligns Voltalia with Uzbekistan’s renewable capacity goals and expands its international footprint in...

Event driven snapshot for Pierre et Vacances Pierre et Vacances (ENXTPA:VAC) continues to attract attention after recent share price moves, with the stock showing mixed short term returns and stronger performance over the past year and past 3 months. See our latest analysis for Pierre et Vacances. The latest share price of €1.854 comes after a small 1 day share price return decline, but the 90 day share price return of 11.96% and 1 year total shareholder return of 23.93% suggest momentum has...

Sanofi (ENXTPA:SAN) shares have been drawing attention after recent performance data, with the stock showing a 1 day return of 0.5% and a 1 year total return decline of 9.2%. See our latest analysis for Sanofi. At a share price of €82.32, Sanofi’s relatively soft 30 day share price return of a 3.15% decline and 1 year total shareholder return of a 9.2% decline indicate that recent momentum has weakened. If you are looking beyond big pharma for more ideas, this could be a useful time to scan...

BNP Paribas (ENXTPA:BNP) has drawn investor attention after recent share price moves, with the stock last closing at €81.92. You might be asking how that level stacks up against its fundamentals. See our latest analysis for BNP Paribas. Recent trading has been positive, with a 1-day share price return of 1.40% and a 30-day share price return of 8.66%, while the 1-year total shareholder return of 50.19% and 5-year total shareholder return of 157.65% point to strong underlying momentum. If BNP...